Bristol Myers Squibb Commits to Veeva Vault CRM

Bristol Myers Squibb (BMS) has committed to Veeva Vault CRM, part of the Vault CRM Suite of applications that provide the technology foundation for commercial execution.

“Technology is fundamentally reshaping the way we engage with our customers and the patients they serve,” said Greg Meyers, executive vice president, chief digital and technology officer at Bristol Myers Squibb. “We are excited to take the next step in our long-standing relationship with Veeva by using Vault CRM to help transform how healthcare practitioners make informed decisions about the increasingly complex array of innovative medicines available today.”

“We appreciate the trust and partnership and are committed to supporting Bristol Myers Squibb in their mission to provide medicines that transform the lives of patients with serious diseases,” said Veeva CEO Peter Gassner. “With Vault CRM we are delivering the next generation of CRM with embedded AI agents to advance healthcare practitioner engagement and help get the right treatments to patients faster.”

The first Veeva AI agents for Vault CRM — Pre-call Agent, Content Agent, Free Text Agent, and Voice Agent — are planned for availability in December 2025.